Opthea Limited (OPT) - News Archive

: Opthea Limited, a clinical-stage biopharmaceutical company, is making significant strides in the development of novel therapies targeting wet age-related macular degeneration (wet AMD). The company’s innovative drug,...

In a transformative era for retinal disease treatment, Opthea Limited is emerging as a beacon of hope for patients suffering from wet age-related macular degeneration (wet AMD). As the company prepares for critical Phas...

In the landscape of retinal disease treatment, the progress towards novel therapies for wet age-related macular degeneration (wet AMD) signifies a crucial development in patient care. Opthea Limited, a clinical-stage bi...

Opthea Announces Promising Findings on VEGF-C and D Signaling Pathways, A Key Milestone in Wet AMD Treatment DevelopmentOpthea, a leading biopharmaceutical company focused on developing innovative therapies for eye dise...

Opthea Limited: Advancing Innovative Therapies for Retinal DiseasesOpthea Limited, a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for prevalent and progressive retinal diseases...

Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMDOpthea, a leading biopharmaceutical company, has accomplished a significant milestone by completing the enrollment of 1,984 pa...

Retina World Congress 2024: Opthea s Milestones in Developing Novel Therapies for Retinal DiseasesOpthea Limited, a clinical-stage biopharmaceutical company, has recently made significant progress in developing innovati...

Opthea, a leading biotechnology company focused on developing treatments for retinal and ophthalmology diseases, recently appointed John Han, PharmD, as the Vice President of Medical Affairs. Han brings with him extensi...

The recent achievement of Opthea Limited, an Australia-based clinical-stage biopharmaceutical company, of gaining a spot in the prestigious 23rd Annual Needham Virtual Healthcare Conference slated for April 11, 2024, is...

The global biopharmaceutical company Opthea Limited has recently announced the appointment of Dr. Arshad M. Khanani, a distinguished retina expert, as their Chief Medical Advisor. This strategic move aims to strengthen...

Opthea s Pivotal Trial Completion Brings New Hope for Wet AMD PatientsOpthea, a clinical-stage biopharmaceutical company specializing in developing novel therapies for ophthalmic diseases, has announced the successful c...

Opthea Strengthens Team to Combat Financial ChallengesIn a strategic move to navigate through financial difficulties, Opthea Limited has recently announced the appointment of two key executives, Dr. Julie Clark as Senio...

Opthea Limited, a clinical-stage biopharmaceutical company focused on developing innovative therapies for retinal diseases, has announced that it is set to receive the remaining $35 million in committed funds under its...